Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time to Market for H2S Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Oct 16, 2021 2:49pm

144 Views

Post# 34013704

RE:RE:RE:RE:RE:Time to Market for H2S Pipeline

We don’t need to be perfect. No drug on planet earth will have 0 LTE. Your stup!dity is nauseating.

StockingUp21 wrote:
Did the rest of the ppl have 0 LTE Could have been everyone almost else who had 4x LTE they only tell us ones who have 5x and more. If this is what happened everything you say is useless

mstrmnd wrote: H2S is not toxic, review the 2a and 2b datasets.

5/42 people with LTE when 3/42 with LTE were expected on a dose ranging AME study does not equal toxicity. There are numerous variables at play and external factors that cannot be ruled out.

The business strategy is clear, data to support short-term or PRN use is there, why go long-term use for OA given AME findings? That's the whole point of doing the AME! Go for the low-hanging fruit and focus on time-to-market.

4 drugs, IP unified, partnership deals in place, $60M on hand and funded to 2024, best time to acquire Antibe is now, waiting longer is risky since H2S clearly has anti-inflammatory + mucosal healing properties and is worth billions - Bayer may loose out and it could go to Chinese or Korean's.

The public market cap is incorrect and there's a significant mismatch with the true value of this company. Canadian exchanges and day-traders have hurt this company significantly.